271 related articles for article (PubMed ID: 1933855)
21. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
Messmann RA; Vitetta ES; Headlee D; Senderowicz AM; Figg WD; Schindler J; Michiel DF; Creekmore S; Steinberg SM; Kohler D; Jaffe ES; Stetler-Stevenson M; Chen H; Ghetie V; Sausville EA
Clin Cancer Res; 2000 Apr; 6(4):1302-13. PubMed ID: 10778955
[TBL] [Abstract][Full Text] [Related]
22. Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice.
Van Horssen PJ; Preijers FW; Van Oosterhout YV; De Witte T
Int J Cancer; 1996 Nov; 68(3):378-83. PubMed ID: 8903481
[TBL] [Abstract][Full Text] [Related]
23. Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma.
Ghetie MA; Podar EM; Gordon BE; Pantazis P; Uhr JW; Vitetta ES
Int J Cancer; 1996 Sep; 68(1):93-6. PubMed ID: 8895546
[TBL] [Abstract][Full Text] [Related]
24. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F
J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
[TBL] [Abstract][Full Text] [Related]
25. Antilymphoma activity of human gamma delta T-cells in mice with severe combined immune deficiency.
Malkovska V; Cigel FK; Armstrong N; Storer BE; Hong R
Cancer Res; 1992 Oct; 52(20):5610-6. PubMed ID: 1394184
[TBL] [Abstract][Full Text] [Related]
26. Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice.
de Kroon JF; de Paus RA; Kluin-Nelemans HC; Kluin PM; van Bergen CA; Munro AJ; Hale G; Willemze R; Falkenburg JH
Exp Hematol; 1996 Jul; 24(8):919-26. PubMed ID: 8690051
[TBL] [Abstract][Full Text] [Related]
27. The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutations which alter their serum half-life.
Pop LM; Liu X; Ghetie V; Vitetta ES
Int Immunopharmacol; 2005 Jul; 5(7-8):1279-90. PubMed ID: 15914332
[TBL] [Abstract][Full Text] [Related]
28. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.
Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Blakey DC; Newell DR
Cancer Res; 1988 Nov; 48(22):6396-403. PubMed ID: 3263186
[TBL] [Abstract][Full Text] [Related]
29. Mouse multivalent IgG(2a, b) antibody--ricin A-chain immunotoxins combined with homologous or heterologous interleukin 2 in the treatment of a murine malignant lymphoproliferation (EL4).
Mota G; Marches R; Cialacu V; Roman V; Kozma E; Mărgineanu M; Dima S; Moraru II
Arch Immunol Ther Exp (Warsz); 1996; 44(2-3):131-6. PubMed ID: 8915518
[TBL] [Abstract][Full Text] [Related]
30. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model.
Vuist WM; v Buitenen F; de Rie MA; Hekman A; Rümke P; Melief CJ
Cancer Res; 1989 Jul; 49(14):3783-8. PubMed ID: 2472198
[TBL] [Abstract][Full Text] [Related]
31. Relationship of the CD22 immunotoxin dose and the tumour establishment in a SCID mice model.
Van Horssen PJ; Preijers FW; Van Oosterhout YV; Eling WM; De Witte T
Leuk Lymphoma; 2000 Nov; 39(5-6):591-9. PubMed ID: 11342342
[TBL] [Abstract][Full Text] [Related]
32. Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model.
Weil-Hillman G; Runge W; Jansen FK; Vallera DA
Cancer Res; 1985 Mar; 45(3):1328-36. PubMed ID: 3971376
[TBL] [Abstract][Full Text] [Related]
33. Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin.
Bonardi MA; Bell A; French RR; Gromo G; Hamblin T; Modena D; Tutt AL; Glennie MJ
Int J Cancer Suppl; 1992; 7():73-7. PubMed ID: 1428411
[TBL] [Abstract][Full Text] [Related]
34. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.
Jansen B; Kersey JH; Jaszcz WB; Gunther R; Nguyen DP; Chelstrom LM; Tuel-Ahlgren L; Uckun FM
Leukemia; 1993 Feb; 7(2):290-7. PubMed ID: 7678881
[TBL] [Abstract][Full Text] [Related]
35. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency.
Gunther R; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Uckun FM
Leukemia; 1993 Feb; 7(2):298-309. PubMed ID: 7678882
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of tumor-reactive immunotoxins in tumor-bearing mice: effect of antibody valency and deglycosylation of the ricin A chain on clearance and tumor localization.
Fulton RJ; Tucker TF; Vitetta ES; Uhr JW
Cancer Res; 1988 May; 48(9):2618-25. PubMed ID: 3258546
[TBL] [Abstract][Full Text] [Related]
38. Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail.
Ghetie MA; Tucker K; Richardson J; Uhr JW; Vitetta ES
Blood; 1994 Aug; 84(3):702-7. PubMed ID: 7519071
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the cytotoxic potency of T101 Fab, F(ab')2 and whole IgG immunotoxins.
Derocq JM; Casellas P; Laurent G; Ravel S; Vidal H; Jansen F
J Immunol; 1988 Oct; 141(8):2837-43. PubMed ID: 3262669
[TBL] [Abstract][Full Text] [Related]
40. The Fc portion of UV3, an anti-CD54 monoclonal antibody, is critical for its antitumor activity in SCID mice with human multiple myeloma or lymphoma cell lines.
Coleman EJ; Brooks KJ; Smallshaw JE; Vitetta ES
J Immunother; 2006; 29(5):489-98. PubMed ID: 16971805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
